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ABSTRACT
There is emerging evidence that the prevalence of 
exercise-induced	 bronchospasm	 (EIB)	 is	 significantly	
under-reported in many sports. Little is known about the 
potential performance improvement that may exist when 
sports	players	are	detected	and	treated	for	EIB,	but	optimal	
airway health is crucial for anyone undertaking regular 
exercise at any level. Athletes may not be aware of an 
underlying	diagnosis	of	EIB,	as	they	may	be	asymptomatic,	
whilst other athletes may present with asthma-like 
symptoms but, upon testing, there is a negative test for 
EIB.	The	pathophysiology	of	 bronchoconstriction	 that	
occurs	in	EIB	differs	from	that	which	occurs	in	normal	
asthma, due to the large volumes of air that pass through 
the respiratory airways resulting in drying out of the aveolar 
fluid with resultant chemical release. A eucapnic voluntary 
hyperpnoea (EVH) challenge is the gold standard to detect 
underlying	EIB	when	it	results	in	a	10%	drop	from	the	
baseline forced expiratory volume in one second (FEV1) 
in comparison to the baseline spirometric FEV1. When 
a negative EVH challenge results, alternative respiratory 
diagnoses must be sought and treated. Hence not all 
exercise related breathing disorders encountered in family 
practice should be labelled as exercise induced asthma 
and treated as such.
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INTRODUCTION 
Exercise induced asthma (EIA) is a condition that is 
overdiagnosed and underdiagnosed throughout the 
physically active population. Overdiagnosis occurs since 
most patients initially present to their family physician 
with various respiratory associated symptoms in relation 
to undertaking exercise. Through lack of understanding of 
what EIA constitutes and possible alternative diagnoses, 
most patients are labelled as ‘exercise induced asthma’ 
and started on the routine inhalers without any proper 
investigation or follow up. A better understanding of EIA 
would enable the family physician to better manage this 
condition as it has been noted that most patients still 
resort to their family physician rather that respiratory 
specialists in order to control their symptoms. Alternative 
diagnoses for exercise related breathing disorders 
may not be considered by family doctors, making the 
overdiagnosis problem larger. Underdiagnosis occurs 
since EIA can affect both the recreational and elite athlete, 
yet it is totally asymptomatic; hence it not easily picked 
up, either by the family doctor or by the patient, unless 
it is considered.
PREVALENCE
The sporting population is known to have a higher 
incidence of asthma than the general population. Athletes 
participating in summer sports have a lower prevalence 
of	 exercise-induced	 bronchospasm	 (EIB)	 than	 those	
practising winter sports, where in the latter the prevalence 
of	 EIB	 can	 range	 between	21-62%	 in	 different	 sports	
(Dickinson, McConnell and Whyte, 2011).
PATHOPHYSIOLOGY OF EIA
EIA occurs when a person undertakes exercise, resulting 
in a large amount of air exchange occurring throughout 
the bronchial and alveolar airways. Usually air is 
humidified through the nasal passages when inhaling, 
but at high levels of exercise these are bypassed, so 
the lower airways are responsible for humidifying the 
inhaled air. This increases the chance of the alveoli 
becoming dehydrated and the surface fluid will increase 
in osmolality. The bronchial epithelial cells respond by 
shrinking and releasing inflammatory mediators which 
results in bronchial constriction that limits airway flow, 
mainly in expiration (Anderson, et al., 1982). EIA is 
always reversible, either spontaneously upon cessation of 
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exercise or else following inhaled-agonists. This process 
is termed bronchoconstriction of the alveolar airways 
resulting in exercise induced asthma, or better termed, 
exercise induced bronchoconstriction.
SCREENING FOR EIB
As already outlined, there is often a potential for over 
or	underdiagnosis	of	EIB,	but	the	main	worry	concerns	
the risk of underdiagnosis. Overdiagnosis can occur 
when	 athletes	 are	diagnosed	with	EIB	on	 the	basis	 of	
reporting symptoms (e.g. cough, wheeze, chest tightness, 
shortness of breath, sputum), where in reality, upon testing 
they	would	be	negative	 for	EIB	 (Ansley,	 et	 al.,	 2012).	
Underdiagnosis can occur when athletes who do not 
report	any	symptoms	will	test	positive	when	tested	for	EIB.
Rundell,	et	al.,	(2001)	found	that	when	EIB	is	gauged	
in	athletes	depending	on	their	symptoms,	only	61%	of	
athletes	with	EIB	were	 detected.	On	 the	 other	 hand,	
45%	of	athletes	with	two	or	more	symptoms	related	to	
asthma	were	not	 found	 to	have	EIB	on	 testing.	Thus,	
positive	symptoms	are	insensitive	to	identifying	EIB	and	
a negative symptom is not specific. The main reason for 
screening	for	EIB	is	to	prevent	any	detrimental	effects	on	
the athlete and the athlete’s performance both during 
training and also during competition. The International 
Olympic Committee Medical Commission (IOC-MC) 
states that all safety measures should be taken to ensure 
that sports does not affect the health or welfare of athletes 
(Samaranch, 1998); thus athletes should be screened 
for	EIB	to	ensure	that	there	is	optimum	airway	health.	
Asthma-related deaths in elite athletes often occur in 
conjunction	with	a	sporting	event	(Becker,	et	al.,	2004),	
and uncontrolled asthma itself plays a significant role in 
unexplained death.
There is increasing evidence that elite athletes fail 
to recognize and/or report symptoms that are related 
to	 EIB,	 as	 was	 described	 by	Dickinson,	McConnell	
and Whyte (2011) when 228 athletes from different 
sporting backgrounds underwent the eucapnic voluntary 
hyperpnoea	 (EVH)	 challenge	 to	 assess	 for	EIB.	 In	 the	
UK, any athlete that competed at the 2008 and 2012 
Olympics	was	screened	for	EIB;	however	non-Olympic	
athletes do not have any guidance as to who should and 
who should not be screened.
Athletes participating in sports where there is the 
presence of certain environmental pollutants are also at 
increased	risk	for	EIB.	Chlorine	compounds	in	swimming	
pools and certain chemicals through car pollution pose 
an additional risk to athletes. These act as allergic triggers 
and may potentially exacerbate bronchospasm in athletes 
who	already	have	increased	susceptibility	to	EIB.	Hence	
it	makes	 it	more	 essential	 to	 screen	 athletes	 for	 EIB.	
EIB	varies	in	its	manifestations	from	mild	performance	
impairment to, rarely, severe bronchospasm with 
respiratory failure. Symptoms are often subtle, such as 
fatigue, or else may occur only in specific environments. 
Despite the fact that not all athletes are aware of ongoing 
EIB	following	exertion,	they	will	recover	spontaneously	
and airflow returns to baseline within 60 minutes, even 
in the absence of bronchodilator intervention.
The research by Dickinson, McConnell and Whyte 
(2011) verified that the presence of symptoms related 
to asthma was found both in athletes with and without 
EIB.	Elite	athletes	may	fail	to	associate	any	dyspnoea	or	
other	respiratory	symptoms	to	EIB,	but	rather	attribute	
this to physical exertion as part of their normal intense 
training or competition regime. Some athletes may also 
avoid	reporting	symptoms	of	EIB	as	they	may	be	under	
the impression that it would signify a weakness on their 
behalf, or that they would risk not being chosen for the elite 
squad.	Hence,	routine	screening	for	EIB	implemented	for	
all athletes would assist in reassuring both the coaches and 
athletes	that	EIB	can	be	detected	and	treated	accordingly	
with	adequate	medication.	This	would	ensure	 that	EIB	
athletes are not at a disadvantage in comparison to their 
non-EIB	fellow	athletes	(Dickinson,	et	al.,	2006).
EUCAPNIC VOLUNTARY 
HYPERPNOEA CHALLENGE
The EVH challenge is the most sensitive test to detect 
EIB	as	it	detects	a	greater	number	of	athletes	that	exhibit	
airway hyper-responsiveness than a sport specific or 
laboratory based exercise challenge (Dickinson, et 
al., 2006). This is because an athlete may undergo a 
laboratory or field test and not encounter the same 
conditions	that	initiate	EIB.	If	there	are	high	humidity	
levels,	 these	may	not	 trigger	EIB,	hence	 giving	 a	 false	
negative result. The EVH challenge is superior to other 
non pharmacological methods of testing since it has a 
tighter control over the main causes of airway hyper-
responsiveness, mainly the inspired water content and 
the minute ventilation. EVH is also paradoxically more 
sensitive	and	specific	for	EIB	than	an	exercise	challenge	
performed either in the laboratory or in the field (Mannix, 
Manfredi and Farber, 1999). 
The EVH challenge is a measure of prevalence of 
bronchial hyper-responsiveness in a group, such as that 
analysed by Holzer, Anderson and Douglass (2002), 
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where	 a	prevalence	of	50%	was	 identified	 and	60%	of	
these had reported asthma symptoms. This is in contrast 
to the methacholine challenge test, undertaken in the 
same	 study,	which	 revealed	 a	prevalence	 of	 only	 18%	
with methacholine. In the latter group, all the subjects 
had reported asthma symptoms. This lends further to the 
evidence that EVH challenge is a more sensitive test for the 
diagnosis of bronchial hyper-responsiveness, than either 
asthma symptoms or methacholine challenge testing.
Initially a baseline spirometry is carried out to 
determine the forced expiratory volume in one second 
(FEV1) and to calculate the target hyperventilation rate 
(30 x FEV1). An EVH challenge is conducted in the 
laboratory which involves the athlete hyperventilating, 
whilst sitting down at rest, for 6 minutes (30 x baseline 
FEV1)	breathing	in	a	gas	mixture	containing	5%	carbon	
dioxide,	21%	oxygen	and	74%	nitrogen.	The	 inspired	
air temperature is 19.1ºC and the relative humidity is 
2%.	 (Anderson,	 et	 al.,	2001).	After,	 the	6	minute	 test	
spirometry is carried out at 3, 5, 7, 10 and 15 minutes 
post test to monitor any change, especially any drop in 
the FEV1.
A fall of ≥10%	 in	 FEV1 following exercise or a 
stimulus	is	considered	to	be	diagnostic	of	EIB	according	
the European Respiratory Society (ERS) and American 
Thoracic Society (ATS) (Roca, et al., 1997). This was 
further widened to state that the fall should occur over 
two consecutive time points, based on the possibility that 
respiratory muscle fatigue can decrease the maximum 
effort needed to perform FEV1 after exercise. This is to 
avoid a poor respiratory effort being misdiagnosed as 
EIB.	The	10%	value	was	chosen	as	this	represents	a	basis	
for limiting exercise performance, and correlates with a 
26%	reduction	in	airway	flow	rates	in	flow	volume	loops	
(Custovic, et al., 1994).
Throughout pharmacological (methacholine or 
histamine)	 testing	of	EIB,	a	 requirement	of	20%	drop	
in FEV1 is commonly applied. However, if this drop is 
applied to an EVH challenge, it will be missing clear cases 
of asthma, yet such a threshold would be highly specific 
for	EIB.	A	threshold	of	10%	drop	in	FEV1 has a sensitivity 
of	63%	and	specificity	of	90%	(Hurwitz,	et	al.,	1995),	and	
this is the recommended level for general use, including 
athletes. In circumstances where avoidance of a false 
positive diagnosis is of utmost important, a threshold 
of	15%	drop	in	FEV1 can be employed, as this is highly 
specific for asthma.
FEV1 was the spirometric parameter that is mostly 
altered following an EVH challenge. It is slightly more 
accurate overall than the forced expiratory flow at 
the	 25%	 point	 to	 the	 75%	 point	 of	 the	 forced	 vital	
capacity (FEF
25-75%
) in distinguishing asthmatics from 
non-asthmatics. If an individual is well motivated, 
peak expiratory flow rate can also be used instead of 
FEV1, but this is more related to effort than the other 
parameters that can be obtained through spirometry. 
Hence it is less useful.
TREATMENT OF EIB
Once	 EIB	 has	 been	 diagnosed,	 through	 obtaining	 a	
positive test on the EVH challenge, proper management 
of	EIB	needs	to	be	addressed.	Athletes	with	a	diagnosis	
of	EIB	should	be	treated	according	to	the	same	British	
Thoracic	Society	(BTS)	guidelines	for	asthma.	The	BTS	
guideline	on	the	management	of	asthma	(British	Thoracic	
Society, 2016) advises a step-wise management plan 
according to severity of the disease, and moving up or 
down the ladder as needed, if control is good for more 
than 3 months.
Step 1:
Occasional short acting inhaled β2-agonist	(SABA)	when	
required for symptomatic relief. If used more than once 
daily or having night time symptoms, go to step 2.
Step 2:
Add inhaled steroid (beclomethasone, budesonide or 
fluticasone) on a regular basis. Short acting β2- agonists 
must not be used as maintenance.
Step 3:
Increase the dose of the inhaled steroid (beclomethasone, 
budesonide, fluticasone). Alternatively a long acting 
β2-agonist	 (LABA),	 salmeterol,	 can	be	added	onto	 the	
inhaled steroid regime. If there are problems with the 
high dose inhaled steroid, go to step 2, and add on 
either a long acting β2-agonist or modified release oral 
theophylline.
Step 4:
Add on ≥1 of the following: inhaled long-acting β2-
agonist, modified release oral theophylline, inhaled 
ipratropium, modified release oral β2-agonist, high dose 
inhaled bronchodilators, cromoglycate or nedocromil.
Step 5:
Add regular oral prednisolone as a one daily dose, 
preferably in the mornings.
8  VOLUME 06 issUE 02 AUGUsT 2017 The Journal of the Malta College of Family Doctors 
It must not be forgotten that athletes are bound 
to the rules and regulations of the World Antidoping 
Association (WADA); hence they may require the use 
of a therapeutic use exemption (TUE) if the athlete 
requires any medication that is in the WADA prohibited 
substances list.
Most	athletes	with	EIB	are	unable	 to	control	 their	
symptoms	with	solely	a	SABA,	thus	a	LABA	is	also	taken	
in	conjunction	with	a	SABA.	However,	over	time	athletes	
with	EIB	are	requiring	additional	doses	of	SABAs	in	order	
to	control	their	EIB,	or	else	the	majority	are	also	resorting	
to the use of inhaled corticosteroids.
A number of findings support this:
•	 a	minority	of	athletes	do	not	have	adequate	EIB	
prevention with β2-agonists when inhaling the 
recommended dose.
•	 daily use of β2-agonists increases the severity of 
EIB	as	well	as	decreasing	the	duration	of	protection	
against	EIB.
•	 once	an	athlete	is	suffering	from	EIB,	the	recovery	
period after inhalation of a β2-agonist is extended, 
the more a β2-agonist is used on a daily basis, as 
well	as	requiring	additional	doses	of	LABA/SABA	to	
achieve the same effect over time.
•	 bronchial hyper-responsiveness can be induced or 
increased by regular use of β2-agonists.
The underlying concept is that there is desensitization 
or tolerance of the β2-receptor as a result of daily drug 
usage	(Bisgaard,	2000),	Desensitisation	is	implicated	to	
occur on the bronchial smooth muscle and/or the mast 
cell due to uncoupling of the receptors and internalization 
or sequestration of uncoupled receptors is followed 
by degradation, resulting in a net downregulation of 
receptors, since receptor resynthesis is not as fast. 
There are also negative findings in relation to the 
regular, daily use of β2-agonists as described by Anderson, 
Caillaud	and	Brannan	(2006):
•	 There exists a minority of asthmatic athletes 
whose	EIB	does	not	respond	to	the	clinically	
recommended dose of β2-agonists. Anderson, 
Caillaud	and	Brannan	(2006) detected 
unexpectedly	high	failure	rates	to	control	EIB	
after	4	weeks	of	regular	treatment	with	a	LABA	
(salmeterol), thus indicating that not all subjects 
have their asthma under control with a regular 
LABA,	and	thus	may	require	the	use	of	inhaled	
corticosteroids for improved control.
•	 Daily	treatment	of	EIB	with	β2-agonists can increase 
the	severity	of	EIB	(Anderson,	Caillaud	and	Brannan,	
2006). This is thought to be due to the enhanced 
release of a preformed mediator such as histamine.
•	 Daily	inhalation	of	LABA	decreases	the	length	of	time	
of	protective	effect	against	EIB.	With	SABA,	protection	
against	EIB	was	not	evident	6.5	hours	after	the	dose	
was	administered.	This	was	seen	in	72%	of	subjects	
with	EIB	who	were	prescribed	a	SABA	(Anderson,	et	
al.,	1991).	In	subjects	who	were	given	LABA,	there	is	
still a reduction in the duration of protection against 
EIB	over	time.	This	tolerance	effect	was	not	affected	
by changing to a once daily dose or by addition of 
a corticosteroid inhaler. The total time in hours of 
protection	against	EIB	was	significantly	decreased	after	
4 weeks and after 8 weeks of treatment, in comparison 
to	just	3	days	of	a	LABA,	namely	salmeterol.
•	 The	recovery	of	EIB	from	a	standard	dose	of	β2-
agonist is slower, when β2-agonists are used on a 
daily basis (Storms, et al., 2004), thus requiring 
additional	doses	from	a	LABA	or	SABA.
•	 Bronchial	hyper-responsiveness	can	be	increased	by	
the daily use of β2-agonists.
MANAGEMENT OF A NEGATIVE 
EVH CHALLENGE
Some athletes may present with exercise related breathing 
difficulties, yet when an EVH challenge is performed, there is 
no drop in the FEV1; hence this is a negative test result, and 
refutes	the	diagnosis	of	EIB.	In	such	cases,	disordered	breathing	
patterns should be looked at and addressed, such as vocal 
cord dysfunction and exercise related laryngeal obstruction. 
In such cases, a good history is also indicative of the problem, 
where the athlete will, upon close questioning, admit to an 
inspiratory, rather than expiratory, difficulty with breathing. 
They will also report a ‘wheeze’, however this is often actually 
stridor, as it is often during the inspiratory aspect of respiration. 
It is often female endurance athletes, who have a tendency to 
anxiety and perfectionism as part of their personality, who have 
a higher tendency to present with this clinical picture, but it is 
not exclusive. In this scenario, various breathing rehabilitation 
techniques need to be implemented for the athlete to control 
the dysfunction and/or obstruction. This would involve learning 
how to perform diaphragmatic breathing in preference to apical 
lung breathing, which is often noted whilst performing the 
EVH challenge, or when asking the patient to inhale and exhale 
deeply a few times in clinic.
Repiratory muscle training, such as through the use 
of a ‘powerbreathe’ aid can help to strengthen respiratory 
The Journal of the Malta College of Family Doctors  VOLUME 06 issUE 02 AUGUsT 2017  9
muscles, including the diaphragm, and allow the athlete 
to learn to ‘relax’ the vocal cords.
A psychologist’s input may be considered for those 
who have a perfectionist or anxious personality or in the 
case of athletes feeling the ‘pressure to perform’, as this 
can be found even at young age groups.
Nevertheless,	it	is	still	worthwhile	screening	for	EIB,	
as both conditions can co-exist and may need to be 
tackled synchronously.
CONCLUSION
Athletes	have	a	higher	prevalence	of	EIB	than	the	general	
population, yet the main concern is that a number of 
these	athletes	do	not	realize	they	have	EIB.
The family doctor is usually the first port of call for 
both elite as well as recreational athletes, hence the 
importance of a detailed history, which can possibly 
elicit	 the	 difference	 between	underlying	EIB	 or	 other	
respiratory issues.
A family doctor may initially opt to treat the athlete as 
EIB,	and	treat	with	appropriate	 inhalers,	according	to	the	
BTS	guidelines.	However,	follow	up	is	important,	as	this	is	
the main area where distinction can be made whether or not 
the athlete is well controlled with inhalers. If upon follow 
up,	the	athlete	still	reports	a	lack	of	control	of	his/her	EIB	
symptoms, it may be worthwhile referring for EVH testing to 
determine	whether	or	not	EIB	is	present,	or	whether	it	is	due	
to alternative breathing patterns that may be impairing normal 
respiration. In this case, inhalers are not recommended.
A history of inspiratory stridor, especially towards the 
end of competition or training helps the family doctor to 
suspect	vocal	cord	dysfunction,	rather	than	EIB,	hence	
respiratory muscle training is more suitable in these 
cases, rather than inhaler based treatment.
The	gold	standard	test	to	refute	or	accept	whether	EIB	
is present or not, still remains an EVH challenge, should 
there be any doubt about the exact diagnosis.
The International Olympic Committee medical 
commission aims to ensure that there is no long lasting 
harm or disease to sports participants. Therefore, athletes 
who	demonstrate	EIB	through	an	EVH	challenge	should	
receive optimal treatment, both for prophylaxis and for 
symptomatic	EIB.
Both	winter	 and	 summer	 sports	 are	 likely	 to	have	
a	high	prevalence	of	EIB.	Hence	this	means	that	there	
are a large number of athletes who fail to recognise and 
report	symptoms	that	may	be	related	to	EIB.	This	makes	
screening of athletes a valuable exercise to ensure optimal 
athlete health.
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